Kim Jialing Png

Kim Png is a Partner at Novo Holdings Seed Investments. She is driving the Singapore Biotech Bridge program, which aims to invest and support innovative biotechnology companies leveraging on Asia innovation capabilities and cross-border opportunities.

Prior to joining Novo Holdings, Kim was a Principal at Polaris Partners, where she focused on venture investments across Asia-Pacific in collaboration with the firm's global investment team. Previously, she spent six years at Temasek, where she invested across private and public biotechnology companies and contributed to the firm's life sciences investment strategy. She was also a founding member of ClavystBio, where she helped build the initial investment portfolio of life sciences startups emerging from Singapore's innovation ecosystem.

Before her investing career, Kim was a scientist and held research and teaching appointments at A*STAR and Nanyang Technological University.

She holds a PhD in Cancer Biology from Rockefeller University, an MBA from Singapore Management University, and a BSE in Biomedical Engineering from Duke University.